Texto: 
PE:  Pelvic Mass  (especially on bimanual under anesthesia)	                 
                                    
Lab: UA - gross hematuria, malignant cytology
Superficial (Carcinoma in Situ):
Endoscopic resection with f/u q3-6 mos
Recurrence: laser therapy or intravesical thiotepa, doxorubicin, mitomycin, or BCG.

Invasive (Extension into muscle or perivesical fat): 
Cystectomy
Radiation treatment

Metastatic (Grim prognosis):
Chemotherapy: cisplatin, methotrexate, doxorubicin, cyclophosphomide, vinblastine
KUB:  Punctate, coarse linear calcifications encrusted on surface or within tumor located in the bladder region suggests malignancy.
Carcinoma of the Bladder
73yo African American male with gross hematuria, otherwise asymptomatic
Demographics: Men 3X's > Women
60-70 years old

Associated with the following:
1.) Exposure to aromatic amines
(2-naphthylamine)
dye, chemical, rubber industries
2.)  Smokers
3.)  Recurrent nephrolithiasis
4.)  Recurrent UTI's
5.)  Travel/Residence in Middle East
chronic schistosomial infections

Present with the following symptoms:

1.) Gross hematuria (75% of patients) Dysuria
2.) Frequency
3.) Urgency (25% of patients)
4.) Pelvic and/or Flank pain
5.) Visceral or osseous pain from metastasis


Keywords: 
\-\ rubber\\ industries\\ 2\\ \\.\\)\ \(0\)\
\-\ recurrent\\ nephrolithiasis\\ 4\\ \\.\\)\ \(0\)\
\-\ flank\\ pain\\ 5\\ \\.\\)\ \(0\)\
\-\ dysuria\\ 2\\ \\.\\)\ \(0\)\
\-\ smokers\\ 3\\ \\.\\)\ \(0\)\
\-\ frequency\\ 3\\ \\.\\)\ \(0\)\
\-\ 5\\ \\.\\)\ \(0\)\
\-\ 4\\ \\.\\)\ \(0\)\
\-\ 1\\ \\.\\)\ \(0\)\
\-\ situ\\ \\)\\:\\ endoscopic\\ resection\ \(0\)\
\-\ grim\\ prognosis\\ \\)\\:\\ chemotherapy\ \(0\)\
\-\ coarse\\ linear\\ calcifications\\ encrusted\ \(1\)\
\-\ bladder\\ region\\ suggests\\ malignancy\ \(1\)\
\-\ 70\\ years\\ old\\ associated\ \(0\)\
\-\ within\\ tumor\\ located\ \(1\)\
\-\ recurrent\\ uti\ \(0\)\
\-\ pelvic\\ mass\ \(33\)\
\-\ otherwise\\ asymptomatic\\ demographics\ \(0\)\
\-\ osseous\\ pain\ \(1\)\
\-\ malignant\\ cytology\\ superficial\ \(0\)\
\-\ following\\ symptoms\ \(2\)\
\-\ 6\\ mos\\ recurrence\ \(0\)\
\-\ 2\ \(13754\)\
\-\ women\\ 60\ \(0\)\
\-\ vinblastine\\ kub\ \(0\)\
\-\ u\\ q3\ \(1\)\
\-\ pelvic\ \(305\)\
\-\ men\\ 3x\ \(0\)\
\-\ laser\\ therapy\ \(4\)\
\-\ intravesical\\ thiotepa\ \(1\)\
\-\ gross\\ hematuria\ \(37\)\
\-\ following\ \(654\)\
\-\ aromatic\\ amines\ \(1\)\
\-\ visceral\ \(22\)\
\-\ urgency\ \(13\)\
\-\ ua\ \(5718\)\
\-\ travel\ \(54\)\
\-\ surface\ \(252\)\
\-\ residence\ \(0\)\
\-\ punctate\ \(39\)\
\-\ pe\ \(20974\)\
\-\ patients\ \(1247\)\
\-\ naphthylamine\ \(1\)\
\-\ muscle\ \(714\)\
\-\ mitomycin\ \(3\)\
\-\ methotrexate\ \(25\)\
\-\ metastasis\ \(206\)\
\-\ lab\ \(1091\)\
\-\ invasive\ \(124\)\
\-\ f\ \(122186\)\
\-\ extension\ \(505\)\
\-\ exposure\ \(113\)\
\-\ especially\ \(223\)\
\-\ dye\ \(5\)\
\-\ doxorubicin\ \(13\)\
\-\ cyclophosphomide\ \(1\)\
\-\ cisplatin\ \(3\)\
\-\ chemical\ \(67\)\
\-\ carcinoma\ \(1182\)\
\-\ bimanual\ \(14\)\
\-\ bcg\ \(0\)\
\-\ anesthesia\ \(32\)\
\-\ 75\ \(204\)\
\-\ 25\ \(658\)\
